Yes, generic Farxiga (dapagliflozin) is now available in the United States. The FDA approved the first generic versions on April 7, 2026, shortly after AstraZeneca’s primary patent expired on April 4, 2026. Multiple generic manufacturers received approval, though availability at your local pharmacy may still be rolling out.
What the Generic Approval Covers
The FDA’s initial generic approval covers two of Farxiga’s uses: reducing the risk of hospitalization for heart failure in adults with type 2 diabetes who also have cardiovascular disease or multiple cardiovascular risk factors, and improving blood sugar control alongside diet and exercise in adults with type 2 diabetes.
Brand-name Farxiga carries additional approved uses, including treating heart failure in adults regardless of diabetes status and slowing the progression of chronic kidney disease. Whether generic dapagliflozin can be prescribed for those broader uses depends on the specific labeling each generic manufacturer received. Your pharmacist can confirm whether the generic version dispensed to you carries the same indications as the brand.
How Generic Dapagliflozin Compares to Brand-Name Farxiga
To earn FDA approval, each generic manufacturer had to demonstrate bioequivalence, meaning their version delivers the same amount of active drug into your bloodstream at the same rate as brand-name Farxiga. The FDA required a single-dose crossover study in healthy adults, measuring dapagliflozin levels in plasma after taking the 10 mg tablet. The 5 mg strength could be approved based on dissolution testing rather than a separate human study, as long as both strengths use proportionally similar formulations.
In practical terms, this means the generic works the same way in your body. The inactive ingredients (fillers, coatings, dyes) may differ, which can occasionally matter if you have a specific allergy to an inactive ingredient. Otherwise, there is no clinical difference between the two.
What Generic Dapagliflozin Costs
Generic dapagliflozin is cheaper than brand-name Farxiga, but the gap is smaller than many people expect for a newly generic medication. Without insurance, brand-name Farxiga runs over $600 for a 30-day supply. The generic starts around $400 at its lowest, depending on the pharmacy. Prices typically drop further as more manufacturers enter the market and competition increases, so costs should come down over the months ahead.
If you have commercial insurance, the price difference may be more dramatic at the pharmacy counter since insurers generally push patients toward generics with lower copays. Check with your plan to see how generic dapagliflozin is covered on your formulary, as tier placement varies.
Savings Options if You’re Still on Brand-Name Farxiga
AstraZeneca still offers a savings card for brand-name Farxiga. If you have commercial insurance, the card can bring your cost to as low as $0 per month, with a maximum savings of $175 per 30-day supply. Cash-paying patients get up to $150 off each monthly prescription and pay the remaining balance out of pocket.
The savings card is not available to anyone enrolled in Medicare Part D, Medicaid, VA, TriCare, or other government-funded prescription programs. It’s also restricted to U.S. and Puerto Rico residents over age 18. If you’re enrolled in any government-subsidized drug benefit, you cannot use the card even if you offer to pay cash.
What to Ask Your Pharmacist
If you’re currently taking brand-name Farxiga, your pharmacy may automatically substitute the generic version the next time you refill, depending on your state’s substitution laws and your prescriber’s instructions. Most states allow pharmacists to swap a brand-name drug for its FDA-approved generic equivalent unless the prescriber specifically writes “dispense as written.”
Before your next refill, it’s worth confirming a few things: whether the generic is in stock at your pharmacy, how your insurance plan covers it compared to the brand, and whether the specific generic version available covers the condition you’re treating. Since the initial generic approval focuses on type 2 diabetes with cardiovascular risk, patients taking Farxiga primarily for heart failure or chronic kidney disease should verify their prescription aligns with the generic’s labeled indications.